David J. Yvars Group’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.04M Buy
903
+10
+1% +$11.8K 0.48% 30
2026
Q2
$1.07M Hold
893
– – 0.51% 28
2026
Q1
$821K Buy
893
+1
+0.1% +$1.01K 0.46% 35
2025
Q4
$959K Buy
892
+12
+1% +$11.5K 0.51% 27
2025
Q3
$672K Hold
880
– – 0.36% 36
2025
Q2
$686K Sell
880
-105
-11% -$81.6K 0.4% 33
2025
Q1
$814K Sell
985
-485
-33% -$404K 0.64% 26
2024
Q4
$1.13M Buy
1,470
+42
+3% +$34.8K 0.69% 23
2024
Q3
$1.27M Buy
1,428
+10
+0.7% +$8.99K 0.78% 23
2024
Q2
$1.28M Buy
1,418
+27
+2% +$21.6K 0.8% 24
2024
Q1
$1.08M Buy
1,391
+485
+54% +$345K 0.73% 26
2023
Q4
$528K Buy
906
+105
+13% +$61.3K 0.42% 33
2023
Q3
$430K Hold
801
– – 0.36% 40
2023
Q2
$376K Hold
801
– – 0.31% 43
2023
Q1
$275K Sell
801
-11,020
-93% -$3.72M 0.25% 56
2022
Q4
$4.32M Sell
11,821
-396
-3% -$140K 5.42% 6
2022
Q3
$3.95M Buy
12,217
+11,421
+1,435% +$3.62M 4.39% 9
2022
Q2
$258K Hold
796
– – 0.35% 47
2022
Q1
$228K Hold
796
– – 0.16% 70
2021
Q4
$220K Buy
+796
New +$202K 0.14% 73

Other funds holding LLY

David J. Yvars Group's LLY Position: Q3 2026 in Review

David J. Yvars Group increased its Eli Lilly (LLY) stake by 1.1% in Q3 2026, buying an estimated $11.8K and bringing the position to 903 shares worth $1.04M. The position accounts for 0.48% of the portfolio, ranked #30.

David J. Yvars Group first reported a position in LLY in Q4 2021 and has held it in 20 quarters since. The position peaked at $4.32M in Q4 2022. 255 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • David J. Yvars Group held 903 shares of Eli Lilly worth $1.04M as of Q3 2026.
  • David J. Yvars Group bought 10 Eli Lilly shares in Q3 2026, an estimated $11.8K.
  • Eli Lilly made up 0.48% of David J. Yvars Group's portfolio in Q3 2026, its #30 holding.
  • David J. Yvars Group first reported a position in Eli Lilly in Q4 2021 and has held it in 20 quarters since.
  • David J. Yvars Group's Eli Lilly position peaked at $4.32M in Q4 2022.
  • 255 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on David J. Yvars Group's 13F filing for Q3 2026, filed 9 Oct 2026.